Primary Results From the Double-Blind, Placebo-Controlled, Phase III SHINE Study of Ibrutinib in Combination With Bendamustine-Rituximab and Rituximab Maintenance as a First-Line Treatment for Older Patients With Mantle Cell Lymphoma
presented at the
30th Congress of the Polish Society of Hematology and Transfusion Medicine, September 8-10, 2022, Bydgoszcz, Poland.
Oral presentation previously presented at the ASCO 2022 Annual Meeting, June 3-7, 2022, Chicago, IL & Online and the EHA2022 Congress, June 9-12, 2022, Vienna, Austria.
Wojciech Jurczak, Steven Le Gouill, Mats Jerkeman, Judith Trotman, Pier Luigi Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, Paul A. Hamlin, Olivier Hermine, José-Ángel Hernández-Rivas, Xiaonan Hong, Seok Jin Kim, David Lewis, Yuko Mishima, Muhit Özcan, Guilherme Fleury Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Martin Dreyling, Michael L. Wang